The U.S. Congress and the Food and Drug Administration have long focused on bringing new therapies to patients with rare diseases, including children.
Read MoreIt has been decided by the Expert Committee that waiver of Clinical trial in Indian population for approval of new drugs, which have already been approved outside India
Read MoreAs per decision taken by the Expert Committee the investigator of clinical trial should not be involved in conduct of more than three clinical trials at a time.
Read MoreMultinational pharmaceutical companies keen to conduct clinical trials for new drugs on Indians would have to ensure an early launch of those therapies in India if the trials result in commercial production, the drug regulator has said.
Read MoreDecided by the Expert Committee, all the sponsors/ manufacturers/ clinical trial applicants have to provide compensation to the trial participant/his/her nominee if any drug- related anomaly is discerned and accepted to be drug related injury or death.
Read MoreToday, “antibiotic resistance” is a widely recognized concern. With the rise of bacteria that are resistant to many, and in some cases, all standard treatments, scientists and medical professionals are not alone in focusing on this problem.
Read MoreThe drugs considered generics and similar biologics (biosimilars) in other countries like USA that have been marketed in such countries for more than four years and have a satisfactory report would be approved for marketing in India
Health minister Dr Harsh Vardhan stated that food business operators (FBO) have to adhere to the advisories and guidelines issued by FSSAI since 2011, the year the Food Safety and Standards Regulations (FSSR) were implemented
FSSAI has extended the deadline for obtaining licences and securing registration for FBOs under FSSR, 2011, by six months. The new deadline is February 4, 2015